Limits...
Genome-wide circulating microRNA expression profiling indicates biomarkers for epilepsy.

Wang J, Yu JT, Tan L, Tian Y, Ma J, Tan CC, Wang HF, Liu Y, Tan MS, Jiang T, Tan L - Sci Rep (2015)

Bottom Line: MicroRNAs (miRNAs) have been proposed as biomarkers for cancer and other diseases due to their stability in serum.Let-7d-5p, miR-106b-5p, -130a-3p and -146a-5p were found up-regulated, whereas miR-15a-5p and -194-5p were down-regulated in epilepsy patients compared to controls (P < 0.0001).Circulating miRNAs were differentially regulated in epilepsy patients as compared with controls.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, Qingdao Municipal Hospital, School of Medicine, Qingdao University, Qingdao, China.

ABSTRACT
MicroRNAs (miRNAs) have been proposed as biomarkers for cancer and other diseases due to their stability in serum. In epilepsy, miRNAs have almost been studied in brain tissues and in animals' circulation, but not in circulation of human. To date, a major challenge is to develop biomarkers to improve the current diagnosis of epilepsy. The aim of this study was to evaluate whether circulating miRNAs can be used as biomarkers for epilepsy. We measured the differences in serum miRNA levels between 30 epilepsy patients and 30 healthy controls in discovery and training phases using Illumina HiSeq2000 sequencing followed by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) assays. The selected miRNAs were then validated in 117 epilepsy patients and 112 healthy controls by qRT-PCR. Let-7d-5p, miR-106b-5p, -130a-3p and -146a-5p were found up-regulated, whereas miR-15a-5p and -194-5p were down-regulated in epilepsy patients compared to controls (P < 0.0001). Among these miRNAs, miR-106b-5p had the best diagnostic value for epilepsy with 80.3% sensitivity and 81.2% specificity. Circulating miRNAs were differentially regulated in epilepsy patients as compared with controls. MiR-106b-5p may serve as a novel, noninvasive biomarker to improve the current diagnosis of epilepsy.

No MeSH data available.


Related in: MedlinePlus

Differential expression levels of significant miRNAs in training phase.Expression levels of the miRNAs were normalized to spiked-in cel-miR-39 and were calculated utilizing the 2−ΔΔCt method. Mann-Whitney U test was used to determine statistical significance. The black dots and stars represent the outliers. The black dots: Values > Qu + 1.5IQR; the stars: Values > Qu + 3.0IQR. Qu, upper quartile; IQR, inter-quartile range.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4379481&req=5

f2: Differential expression levels of significant miRNAs in training phase.Expression levels of the miRNAs were normalized to spiked-in cel-miR-39 and were calculated utilizing the 2−ΔΔCt method. Mann-Whitney U test was used to determine statistical significance. The black dots and stars represent the outliers. The black dots: Values > Qu + 1.5IQR; the stars: Values > Qu + 3.0IQR. Qu, upper quartile; IQR, inter-quartile range.

Mentions: The expression levels of the 10 miRNAs selected by high-throughput sequencing were determined using real-time quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) in a cohort of 30 epilepsy patients and 30 healthy individuals. MiRNA levels were normalized to spiked-in cel-miR-39. All samples were measured in triplicates and the mean values were used for analysis. Only miRNAs with a Cq value < 36, a detection rate > 75% in both groups, and a p value < 0.05 were selected for further analyses6. As a result, miR-15a-5p, -194-5p and novel-mir-96 were significantly decreased in epilepsy patients when compared with controls (P = 2.5 × 10−5, 7.1 × 10−22, 3.6 × 10−4, respectively); while let-7d-5p, miR-106b-5p, -130a-3p, and -146a-5p were elevated in epilepsy patients (P = 0.001, 6.0 × 10−5, 6.3 × 10−8, 0.001, respectively) (Fig. 2). The detection rates of miR-889-3p were less than 75%; no significant difference was observed in the levels of miR-144-5p, and -181c-5p between epilepsy patients and controls (P > 0.05).


Genome-wide circulating microRNA expression profiling indicates biomarkers for epilepsy.

Wang J, Yu JT, Tan L, Tian Y, Ma J, Tan CC, Wang HF, Liu Y, Tan MS, Jiang T, Tan L - Sci Rep (2015)

Differential expression levels of significant miRNAs in training phase.Expression levels of the miRNAs were normalized to spiked-in cel-miR-39 and were calculated utilizing the 2−ΔΔCt method. Mann-Whitney U test was used to determine statistical significance. The black dots and stars represent the outliers. The black dots: Values > Qu + 1.5IQR; the stars: Values > Qu + 3.0IQR. Qu, upper quartile; IQR, inter-quartile range.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4379481&req=5

f2: Differential expression levels of significant miRNAs in training phase.Expression levels of the miRNAs were normalized to spiked-in cel-miR-39 and were calculated utilizing the 2−ΔΔCt method. Mann-Whitney U test was used to determine statistical significance. The black dots and stars represent the outliers. The black dots: Values > Qu + 1.5IQR; the stars: Values > Qu + 3.0IQR. Qu, upper quartile; IQR, inter-quartile range.
Mentions: The expression levels of the 10 miRNAs selected by high-throughput sequencing were determined using real-time quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) in a cohort of 30 epilepsy patients and 30 healthy individuals. MiRNA levels were normalized to spiked-in cel-miR-39. All samples were measured in triplicates and the mean values were used for analysis. Only miRNAs with a Cq value < 36, a detection rate > 75% in both groups, and a p value < 0.05 were selected for further analyses6. As a result, miR-15a-5p, -194-5p and novel-mir-96 were significantly decreased in epilepsy patients when compared with controls (P = 2.5 × 10−5, 7.1 × 10−22, 3.6 × 10−4, respectively); while let-7d-5p, miR-106b-5p, -130a-3p, and -146a-5p were elevated in epilepsy patients (P = 0.001, 6.0 × 10−5, 6.3 × 10−8, 0.001, respectively) (Fig. 2). The detection rates of miR-889-3p were less than 75%; no significant difference was observed in the levels of miR-144-5p, and -181c-5p between epilepsy patients and controls (P > 0.05).

Bottom Line: MicroRNAs (miRNAs) have been proposed as biomarkers for cancer and other diseases due to their stability in serum.Let-7d-5p, miR-106b-5p, -130a-3p and -146a-5p were found up-regulated, whereas miR-15a-5p and -194-5p were down-regulated in epilepsy patients compared to controls (P < 0.0001).Circulating miRNAs were differentially regulated in epilepsy patients as compared with controls.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, Qingdao Municipal Hospital, School of Medicine, Qingdao University, Qingdao, China.

ABSTRACT
MicroRNAs (miRNAs) have been proposed as biomarkers for cancer and other diseases due to their stability in serum. In epilepsy, miRNAs have almost been studied in brain tissues and in animals' circulation, but not in circulation of human. To date, a major challenge is to develop biomarkers to improve the current diagnosis of epilepsy. The aim of this study was to evaluate whether circulating miRNAs can be used as biomarkers for epilepsy. We measured the differences in serum miRNA levels between 30 epilepsy patients and 30 healthy controls in discovery and training phases using Illumina HiSeq2000 sequencing followed by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) assays. The selected miRNAs were then validated in 117 epilepsy patients and 112 healthy controls by qRT-PCR. Let-7d-5p, miR-106b-5p, -130a-3p and -146a-5p were found up-regulated, whereas miR-15a-5p and -194-5p were down-regulated in epilepsy patients compared to controls (P < 0.0001). Among these miRNAs, miR-106b-5p had the best diagnostic value for epilepsy with 80.3% sensitivity and 81.2% specificity. Circulating miRNAs were differentially regulated in epilepsy patients as compared with controls. MiR-106b-5p may serve as a novel, noninvasive biomarker to improve the current diagnosis of epilepsy.

No MeSH data available.


Related in: MedlinePlus